J Clin Oncol. 2025 Jan 9. IF: 42.1
Trastuzumab-Pertuzumab Plus Eribulin or Taxane as First-Line Chemotherapy for Human Epidermal Growth Factor 2-Positive Locally Advanced/Metastatic Breast Cancer: The Randomized Noninferiority Phase III EMERALD Trial.
www.ascopubs.org/doi/10.1200/JCO-24-01888
Nat Immunol. 2025 Jan 9. IF: 27.7
Low-avidity T cells drive endogenous tumor immunity in mice and humans.
www.nature.com/articles/s41590-024-02044-z
Mol Cancer. 2025 Jan 8;24:6. IF: 27.7
Intra-tumoral sphingobacterium multivorum promotes triple-negative breast cancer progression by suppressing tumor immunosurveillance.
www.biomedcentral.com/articles/10.1186/s12943-024-02202-9
Nat Biomed Eng. 2025 Jan 9. IF: 26.8
Interpretable identification of cancer genes across biological networks via transformer-powered graph representation learning.
www.nature.com/articles/s41551-024-01312-5
JAMA Oncol. 2025 Jan 9. IF: 22.5
Weight Changes and Heart Failure Risk After Breast Cancer Development.
www.jamanetwork.com/journals/jamaoncology/fullarticle/2828795
JAMA Oncol. 2025 Jan 9. IF: 22.5
Genetic Ancestry-Based Differences in Biomarker-Based Eligibility for Precision Oncology Therapies.
www.jamanetwork.com/journals/jamaoncology/fullarticle/2828797
Nucleic Acids Res. 2025 Jan 7;53(1):gkae1250. IF: 16.6
Design and in vitro anticancer assessment of a click chemistry-derived dinuclear copper artificial metallo-nuclease.
www.academic.oup.com/nar/article/7944736
Nat Commun. 2025 Jan 9;16:541. IF: 14.7
CDK4 inactivation inhibits apoptosis via mitochondria-ER contact remodeling in triple-negative breast cancer.
www.nature.com/articles/s41467-024-55605-z
Nat Commun. 2025 Jan 9;16:557. IF: 14.7
DCAF13-mediated K63-linked ubiquitination of RNA polymerase I promotes uncontrolled proliferation in Breast Cancer.
www.nature.com/articles/s41467-025-55851-9
Nat Commun. 2025 Jan 8;16:505. IF: 14.7
Predicting cell morphological responses to perturbations using generative modeling.
www.nature.com/articles/s41467-024-55707-8
J Am Chem Soc. 2025 Jan 8. IF: 14.4
Monitoring of the Local Extracellular Environment Using Chiral Gold Nanoparticles.
pubs.acs.org/doi/10.1021/jacs.4c16686
Cancer Res. 2025 Jan 9. IF: 12.5
Oxidative Phosphorylation is a Metabolic Vulnerability of Endocrine Therapy-Tolerant Persister Cells in ER+ Breast Cancer.
www.aacrjournals.org/cancerres/article/750883
Cancer Res. 2024 Dec 30. IF: 12.5
ST6GAL1-Mediated Sialylation of PECAM-1 Promotes a Transcellular Diapedesis-Like Process that Directs Lung Tropism of Metastatic Breast Cancer.
www.aacrjournals.org/cancerres/article/750755
Carbohydr Polym. 2025 Mar 1;351:123123. IF: 10.7
Hijacking the hyaluronan assisted iron endocytosis to promote the ferroptosis in anticancer photodynamic therapy.
www.sciencedirect.com/science/article/pii/S0144861724013493
Carbohydr Polym. 2025 Mar 1;351:123062. IF: 10.7
Elucidation of the fine structure and anti-breast tumor activity of a glucomannan from the pseudobulbs of Pleione bulbocodioides.
www.sciencedirect.com/science/article/pii/S0144861724012888
Biosens Bioelectron. 2025 Jan 7;272:117129. IF: 10.7
Unveiling the susceptibility of nanosecond pulsed electric field on intracellular function in breast cancerous and normal cells using fluorescence imaging.
www.sciencedirect.com/science/article/pii/S095656632500003X
Plant Biotechnol J. 2025 Jan 7. IF: 10.1
Comparative bioactivity analysis of latex and water extract of Euphorbia gaillardotii: chemical profile, antioxidant capacity, effects on water quality, in vitro antimicrobial-cytotoxic activities, and in silico molecular docking studies.
www.onlinelibrary.wiley.com/doi/10.1111/pbi.14525
Clin Cancer Res. 2024 Dec 30. IF: 10.0
RAD51 testing in patients with early HER2-negative breast cancer and homologous recombination deficiency: post-hoc analysis of the GeparOla trial.
www.aacrjournals.org/clincancerres/article/750751
Clin Cancer Res. 2025 Jan 9. IF: 10.0
Ultrasensitive Detection and Monitoring of Circulating Tumor DNA using Structural Variants in Early-Stage Breast Cancer.
www.aacrjournals.org/clincancerres/article/750974
Clin Nucl Med. 2025 Jan 9. IF: 9.6
FAP-Targeted SPECT/CT and PET/CT Imaging for Breast Cancer Patients.
www.lww.com/10.1097/RLU.0000000000005617
Biomark Res. 2025 Jan 9;13(1):6. IF: 9.5
MORF4L2 induces immunosuppressive microenvironment and immunotherapy resistance through GRHL2/MORF4L2/H4K12Ac/CSF1 axis in triple-negative breast cancer.
www.biomedcentral.com/articles/10.1186/s40364-024-00719-1
Proc Natl Acad Sci U S A. 2025 Jan 9;122(2):e2421710122. IF: 9.4
A signaling molecule from intratumor bacteria promotes trastuzumab resistance in breast cancer cells.
www.pnas.org/doi/10.1073/pnas.2421710122
